Background Riluzole is approved for the treatment of amyotrophic lateral sclerosis in most
countries. Questions persist about its clinical utility because of high cost and modest efficacy …

As with other chronic neurologic diseases, many of the problems engendered by the
disease can be managed effectively with a beneficial impact on quality of life and m some …

BACKGROUND: Riluzole 100 mg probably prolongs survival in patients with amyotrophic
lateral sclerosis by about two months and the safety of the drug is not a major concern. The …

Riluzole is to date the only treatment that prolongs amyotrophic lateral sclerosis (ALS)
survival. However, results on the efficacy of riluzole in observational population‐based …

A great majority of people with neuromuscular diseases like muscular dystrophy, ALS, spinal
muscular atrophy, myasthenia gravis and post-poliomyelitis continue to be told that they …

Motor neurone disease is a progressive neurodegenerative disorder leading to severe
disability and death. It is clinically characterised by mixed upper and lower motor neurone …

Mission statement. The Quality Standards Subcommittee (QSS) of the American Academy of
Neurology (AAN) is charged with developing practice parameters for physicians. This …

Results. The improvement level for paroxysmal limb pain or burning paresthesias was+++ in
2 patients,++ in 5,+ in 1, and 0 in 1; in 8 patients improvement persisted after 1 year …

Objective: In patients with amyotrophic lateral sclerosis, long term treatment with riluzole has
been reported to improve survival or tracheostomy-free survival in comparison with placebo …

Amyotropic lateral sclerosis (ALS) is a progressive degenerative condition of motor neurons
that is ultimately fatal. Even though scientific discovery over the past few decades has led to …